Review: moderately early postnatal corticosteroids reduce chronic lung disease and mortality in preterm infants, but increase complications


**QUESTIONS:** Is moderately early postnatal corticosteroid (PC) treatment given 7–14 days after birth effective for prevention and treatment of chronic lung disease (CLD) in at risk, preterm infants? Do PCs increase the risk of adverse effects?

### Data sources

Studies were identified by searching the Oxford Database of Perinatal Trials, the Cochrane Controlled Trials Register, and Medline (1966 to September 2000); handsearching paediatric and perinatal journals; examining review articles; and contacting practise neonatologists.

### Study selection

Randomised controlled trials were selected if they compared systemic PC treatment given 7–14 days after birth with control (placebo or nothing) in preterm infants with or at risk of developing CLD.

### Data extraction

Data were extracted on study methods, participant characteristics, and outcomes.

### Main results

7 trials (8 treatment arms) were included in the analysis. The trials involved very low birthweight infants who were receiving mechanical ventilation; the corticosteroid was dexamethasone, with a starting dose of 0.5 mg/kg/day and a duration of 2–42 days. Meta-analysis showed that moderately early PC treatment reduced mortality at 28 days (but not mortality before discharge [6 studies, n=288]), CLD at 28 days and 36 weeks postmenstrual age, combined death or CLD at 28 days and 36 weeks, and need for late steroid treatment (table); but increased risk of hyperglycaemia, hypertension, hypertrophic cardiomyopathy, gastrointestinal bleeding, and infection, (table). It did not affect long term outcomes of abnormal neurological examination (1 study, n=56) or combined death or abnormal neurological examination (1 study, n=56).

### Conclusion

Moderately early corticosteroid treatment 7–14 days after birth reduces chronic lung disease and mortality in at risk, preterm infants, but increases risk of metabolic and gastrointestinal complications and infection.

---

### Outcomes

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Number of studies (n)</th>
<th>Early PCs</th>
<th>Control</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic lung disease (CLD) at 28 days</td>
<td>6 (623)</td>
<td>76%</td>
<td>87%</td>
<td>13% (6 to 19)</td>
<td>10 (6 to 17)</td>
</tr>
<tr>
<td>CLD at 36 weeks postmenstrual age</td>
<td>5 (247)</td>
<td>34%</td>
<td>55%</td>
<td>38% (16 to 53)</td>
<td>5 (3 to 12)</td>
</tr>
<tr>
<td>Death or CLD at 28 days</td>
<td>4 (520)</td>
<td>62%</td>
<td>96%</td>
<td>14% (9 to 19)</td>
<td>8 (6 to 13)</td>
</tr>
<tr>
<td>Death or CLD at 36 weeks postmenstrual age</td>
<td>5 (247)</td>
<td>45%</td>
<td>72%</td>
<td>37% (22 to 49)</td>
<td>4 (3 to 7)</td>
</tr>
<tr>
<td>Need for late steroids</td>
<td>5 (545)</td>
<td>12%</td>
<td>24%</td>
<td>50% (29 to 65)</td>
<td>9 (6 to 17)</td>
</tr>
</tbody>
</table>

### Table

<table>
<thead>
<tr>
<th>Weighted event rates</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperglycaemia</td>
<td>3 (659)</td>
<td>35%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6 (599)</td>
<td>8%</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy</td>
<td>3 (168)</td>
<td>27%</td>
</tr>
<tr>
<td>Gastrointestinal bleeding</td>
<td>3 (485)</td>
<td>14%</td>
</tr>
<tr>
<td>Infection</td>
<td>7 (659)</td>
<td>33%</td>
</tr>
</tbody>
</table>

### Notes


**COMMENTARY—continued from previous page**

The review concluded that both early and moderately early PCs reduce CLD and the combined outcome of CLD or mortality. Although these benefits are substantial, the reviews also confirm that both early and moderately early PCs increase the risk of short term gastrointestinal and metabolic complications. These complications are clinically significant and present a dilemma to clinicians weighing the risks and benefits of this treatment. Evidence also suggests that early PCs increase the incidence of cerebral palsy and developmental delay. Because this finding is based on only 2 studies, further research is needed. Growth is another area of concern for clinicians and parents, and the review suggests early PCs are associated with growth failure. The effect of corticosteroids on growth is another area for further investigation.

It is important for clinicians caring for preterm infants to be aware of the short term adverse effects so that they can manage these conditions appropriately. The authors also emphasised the urgent need for further follow up studies of existing randomised controlled trials of postnatal steroids given at any time after birth.

In view of the serious nature of the risks involved, the use of PCs should be reserved for situations where the benefits clearly exceed the risks.

Anne Major, RGN, RM
Clinical Facilitator, Neonatal Unit
Sharoe Green Hospital Preston, Lancashire, UK
Review: moderately early postnatal corticosteroids reduce chronic lung disease and mortality in preterm infants, but increase complications

*Evid Based Nurs* 2002 5: 10
doi: 10.1136/ebn.5.1.10

Updated information and services can be found at:
http://ebn.bmj.com/content/5/1/10

These include:

**References**
This article cites 2 articles, 2 of which you can access for free at:
http://ebn.bmj.com/content/5/1/10#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Child health (466)
- Hypertension (220)
- Infant health (122)
- Mechanical ventilation (35)
- Neonatal health (66)
- Cardiomyopathy (4)
- Diabetes (189)
- Drugs: cardiovascular system (269)
- Drugs: respiratory system (37)
- GI bleeding (8)
- Immunology (including allergy) (328)
- Internet (387)
- Mechanical ventilation (35)
- Metabolic disorders (155)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/